Mr. Zach Stadnyk reports

SUPREME COMPLETES PRIVATE PLACEMENT FOR AGGREGATE TOTAL OF $1.78M

Supreme Pharmaceuticals Inc. has closed the final tranche of its previously announced unit financing for gross proceeds of $815,893.44. At the final closing, Supreme issued 2,549,667 units (comprising 2,549,667 common shares of the company and 1,274,834 common share purchase warrants) at a price of 32 cents per unit. Each warrant is exercisable for one common share at a price of 50 cents per share prior to Nov. 17, 2016, subject to an accelerated expiry period upon 30-day notice by the company to the subscriber, if the common shares trade at or above 70 cents for any five-day period during the term of the warrants. Gross proceeds raised from the first and second closings totalled $1,781,642.24 through the issuance of 5,567,632 common shares and 2,783,816 warrants.

"Having raised almost double the proceeds that we initially sought when we announced our raise just three weeks ago, we're pleased with the positive response we've had and extremely gratified at the investment community's ongoing interest in Supreme," stated a director of the company. "With this raise now finalized, we have a strong balance sheet and are well positioned to continue executing on our long-term growth strategy."

The company paid total finders' fees of $21,769.60 and issued 68,030 warrants to certain arm's-length parties in the connection with the subscriptions of certain subscribers who participated in the financing.

The common shares and warrants issued pursuant to the final tranche of the financing are subject to a hold period that expires March 18, 2015. Following closing, Supreme has 76,031,197 common shares issued and outstanding.

The company intends to use the total proceeds of the financing for the continuing development of the company's Kincardine facility and general working capital purposes.

We seek Safe Harbor.